Michelle M. Mielke, PhD is Professor and Chair of the Department of Epidemiology and Prevention in the Division of Public Health Sciences and a Professor of Gerontology and Geriatrics Medicine at Wake Forest University School of Medicine.  Her primary research interests include identifying and implementing fluid biomarkers for the diagnosis, prediction, and progression of Alzheimer's disease, and examining sex and gender differences in the development and progression of Alzheimer’s disease and of other aging-related conditions. She is the principal investigator or collaborator on an extensive portfolio of NIH, DOD and other extramurally supported grants and contracts. In addition, Dr. Mielke is a member of the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee and has served on several panels within the NIH, DOD, and CDC. She has previously served as Chair of the Biofluid Based Biomarker (BBB) Professional Interest Area of the Alzheimer’s Association and is currently a member of the Global Biomarkers Standardization of CSF Biomarkers (GBSC), the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group, and co-Chairs the Global CEOi Blood-Based Biomarker Implementation Workgroup. Dr. Mielke has also been involved in the development of recommendations for the use of blood-based biomarkers for clinical and research purposes. She received the John R. Raymond Mentor Award from the Women Scholars Initiative and is a Fellow in the American Association for the Advancement of Science (AAAS), Section on Neuroscience.